Safety, Tolerability, and Pharmacokinetics of PTG-200, An Oral GI-restricted Peptide Antagonist of IL-23 Receptor, In Normal Healthy Volunteers

(1) Protagonist Therapeutics,Newark,United States

(2) Myovant Sciences,Brisbane,United States

(3) None,Saratoga,United States

(4) Protagonist Therapeutics Inc.,Newark,United States

(5) Applied Molecular Transport,South San Francisco,United States



This item was part of the IBD II (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019